Heart failure therapy with bisoprolol: Efficiency and costs in France from CIBIS II;Bisoprolol dans l'insuffisance cardiaque: Efficacité et coûts dans le cadre Français selon CIBIS II

Therapie

Volumn , Issue 4, 2001, Pages 421-425

  Levy P ^a   Merot J L ^b   Lechat, Ph ^c   Levy E ^a   Bogillot, O ^d  

^a UNIVERSITÉ PARIS DAUPHINE   (France)

^b Quiantiles SA   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d Lipha SA   (France)

Author keywords

Beta blockers; Bisoprolol; CIBIS II; Cost effectiveness; Heart failure

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARDENSIEL; CARDIAC GLYCOSIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; FRANCE; HEART FAILURE; HOSPITAL COST; HUMAN; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH INSURANCE; PRIORITY JOURNAL; SURVIVAL; CONGESTIVE HEART FAILURE; COST BENEFIT ANALYSIS; COST CONTROL; DOUBLE BLIND PROCEDURE; ECONOMICS; FOLLOW UP; HOSPITALIZATION; LIFE EXPECTANCY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICS;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; BISOPROLOL; COST CONTROL; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; DRUG COSTS; FEMALE; FOLLOW-UP STUDIES; FRANCE; HEART FAILURE, CONGESTIVE; HOSPITALIZATION; HUMANS; LIFE EXPECTANCY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 0034741208     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. McMurray J, Davie A. The pharmacoeconomics of ACE inhibitors in chronic heart failure. PharmacoEconomics 1996; 3: 188-197.
2. McMurray J et al. Clinical epidemiology of heart failure: public and private health burden. Eur Heart J 1998; 19: 9-16.
3. Delahaye F et al. Epidémiologie et impact économique de l'insuffisance cardiaque en France. Arch Mal Coeur Vaiss 1998; 91: 1307-1314.
4. Launois R et al. Le coût de la sévérité de la maladie: le cas de l'insuffisance cardiaque. J d'Economie Medicale 1990; 8: 395-412.
5. Levy F. From cost of illness to cost-effectiveness in heart failure. Eur Heart J 1998; 19: 2-4.
6. The Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. 3-year follow-up of patients randomised in the Metropolol in Dilated Cardiomyopathy Trial. Lancet 1998; 351: 1180-1181.
7. Waagstein F et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993; 342: 1441-1446.
8. Packer M et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349-1355.
9. Australia-New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997; 349: 375-380.
10. Bonet S et al. Beta-adrenergic blocking agents in heart failure: benefits of vasodilating and non-vasodilating agents according to patients' characteristics: a meta-analysis of clinical trials. Arch Intent Med 2000; 160(5): 621-627.
11. Doughty R et al. Effects of beta-blocker therapy on mortality in patients with heart failure: a systematic overview of randomised controlled trials. Eur Heart J 1997; 8: 560-565.
12. Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coil Cardiol 1997; 30(1): 27-34.
13. Landray MJ. Kendall MJ. Beta-blockers in heart failure - a cardioprotective therapy? J Clin Pharm Ther 1997; 22(3): 181-185.
14. Lechat P et al. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials [see comments]. Circulation 1998; 98(12): 1184-1191.
15. Schmidt BM, Janson CP, Wehling M. Assuming the worst may not be bad at all. Carvedilol in heart failure treatment [published erratum appears in Eur J Clin Pharmacol 1998; 54(6):493]. Eur J Clin Pharmacol 1998; 54(4): 281-285.
16. Eichhorn EJ. Experience with beta blockers in heart failure mortality trials. Clin Cardiol 1999; 22 (Suppl 5): V21-29.
17. CIBIS Investigators and Committees. A randomized trial of b-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994; 90: 1765-1773.
18. Anthonio RL et al. Different effects of bisoprolol on heart rate in patients with ischemic or idiopathic dilated cardiomyopathy (a 24-hour Holter substudy of the Cardiac Insufficiency Bisoprolol Study [CIBIS]). Am J Cardiol 1999; 83(8): 1286-1289, A10.
19. Funck-Brentano C et al. Predictors of medical events in patients enrolled in the cardiac insufficiency bisoprolol study (CIBIS): a study of the interactions between beta-blocker therapy and occurrence of critical events using analysis of competitive risks. Am Heart J 2000; 139(2 Pt 1): 262-271.
20. Levy P et al. A cost-minimization of heart failure therapy with bisoprolol in the French setting: an analysis from CIBIS trial data. Cardiac Insufficiency Bisoprolol Study. Cardiovasc Drugs Ther 1998; 12(3): 301-305.
21. CIBIS investigators and committees. Design of the Cardiac Insufficiency Bisoprolol Study II (CIBIS II). Fund Clin Pharmacol 1997; 11: 38-42.
22. CIBIS investigators and committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353(9146): 9-13.
23. PMSI. Site officiel du PMSI. http://www.le-pmsi.fr/.
24. Service Contrôle et Normes de Gestion. Comptabilité analytique hospitalière des hôpitaux, fiches détaillées par activité el service. Résultats de l'année 1997. Paris: Assistance Publique Hôpitaux de Paris, 1998.